Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.

Hdl Handle:
http://hdl.handle.net/10147/229117
Title:
Anti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.
Authors:
Korpanty, Grzegorz; Smyth, Elizabeth
Affiliation:
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland. greg.korpanty@gmail.com.
Citation:
Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. 2012, 18 (19):2680-701 Curr. Pharm. Des.
Journal:
Current pharmaceutical design
Issue Date:
2012
URI:
http://hdl.handle.net/10147/229117
PubMed ID:
22390756
Abstract:
Tumour angiogenesis (formation of new blood vessels supporting tumour growth and metastasis) is a result of complex interactions between the tumour and the surrounding microenvironment. Targeting tumours with anti-angiogenic therapy remains an exciting area of preclinical and clinical studies. Although many significant advances have been achieved and the clinical use of anti-angiogenic drugs is now well recognized in many solid malignancies, these therapies fall short of their anticipated clinical benefits and leave many unanswered questions like exact mechanism of action, patients' selection and monitoring response to anti-angiogenic drugs. Tumour angiogenesis is controlled by complex signaling cascades and ongoing research into molecular mechanisms of tumour angiogenesis not only helps to understand its basic mechanisms but hopefully will identify new therapeutic targets. In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies.
Item Type:
Article
Language:
en
ISSN:
1873-4286

Full metadata record

DC FieldValue Language
dc.contributor.authorKorpanty, Grzegorzen_GB
dc.contributor.authorSmyth, Elizabethen_GB
dc.date.accessioned2012-06-15T13:44:28Z-
dc.date.available2012-06-15T13:44:28Z-
dc.date.issued2012-
dc.identifier.citationAnti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer. 2012, 18 (19):2680-701 Curr. Pharm. Des.en_GB
dc.identifier.issn1873-4286-
dc.identifier.pmid22390756-
dc.identifier.urihttp://hdl.handle.net/10147/229117-
dc.description.abstractTumour angiogenesis (formation of new blood vessels supporting tumour growth and metastasis) is a result of complex interactions between the tumour and the surrounding microenvironment. Targeting tumours with anti-angiogenic therapy remains an exciting area of preclinical and clinical studies. Although many significant advances have been achieved and the clinical use of anti-angiogenic drugs is now well recognized in many solid malignancies, these therapies fall short of their anticipated clinical benefits and leave many unanswered questions like exact mechanism of action, patients' selection and monitoring response to anti-angiogenic drugs. Tumour angiogenesis is controlled by complex signaling cascades and ongoing research into molecular mechanisms of tumour angiogenesis not only helps to understand its basic mechanisms but hopefully will identify new therapeutic targets. In 2012, both monoclonal antibodies and small molecule tyrosine kinase inhibitors remain the two major clinically useful therapeutic options that interfere with tumour angiogenesis in many solid malignancies.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Current pharmaceutical designen_GB
dc.titleAnti-VEGF strategies - from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland. greg.korpanty@gmail.com.en_GB
dc.identifier.journalCurrent pharmaceutical designen_GB
dc.description.provinceLeinsteren
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.